Enanta Pharmaceuticals (ENTA) Expected to Announce Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is anticipated to release its Q4 2026 resultson Monday, November 16th. Analysts expect Enanta Pharmaceuticals to post earnings of ($0.7240) per share and revenue of $14.62 million for the quarter. Investors can check the company’s upcoming Q4 2026 earnings report page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. On average, analysts expect Enanta Pharmaceuticals to post ($2.36) EPS for the current fiscal year and ($2.50) EPS for the next fiscal year.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA opened at $11.00 on Monday. The firm has a market capitalization of $320.32 million, a PE ratio of -4.56 and a beta of 0.75. The firm’s 50-day moving average is $12.19 and its two-hundred day moving average is $13.12. Enanta Pharmaceuticals has a 1 year low of $10.05 and a 1 year high of $17.15.

Analyst Ratings Changes

ENTA has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, October 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), and other serious infectious diseases.

Enanta’s most notable commercial contribution is its discovery of glecaprevir, an active component of the hepatitis C treatment Mavyret, also marketed as Maviret outside the United States.